All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Swaminathan presented a poster during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, reporting long-term findings of a phase II study (NCT03404193) of venetoclax in combination with 10-day decitabine in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). |
Key learnings |
Among patients with newly diagnosed (ND) AML (n = 88), untreated secondary AML (sAML; n = 17), treated sAML (n = 30), relapsed/refractory (R/R) AML (n = 72), and high-risk MDS (n = 21):
|
Among patients with ND AML, untreated sAML, treated sAML, and R/R AML:
|
Patients receiving stem cell transplantation (SCT) had improved survival outcomes compared with those not receiving SCT. |
Safety findings were consistent with the known safety profile of venetoclax + hypomethylating agents. Most common treatment-emergent adverse events were infection with absolute neutrophil count <1.0 × 109/L (42%) and >1.0 × 109/L (38%), febrile neutropenia (32%), thrombocytopenia (16%), neutropenia (13%), and oral mucositis (13%). |
Venetoclax in combination with 10-day decitabine was highly effective and well tolerated in older/unfit patients with ND and R/R AML; however, more clinical trials are needed to validate the findings. |
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox